#Biotechnology #AutoimmuneDiseases #ClinicalTrials
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.
#Neuroscience #Alzheimers #ClinicalTrials
www.nasdaq.com
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) has entered 2026 with momentum, announcing positive Phase 1b results for its lead candidate NMRA-511 in Alzheimer's disease agitation, along with a pipeline strategy that promises multiple clinical readouts across its neuroscience programs.
#NeumoraTherapeutics #Alzheimers #ClinicalTrials
www.nasdaq.com
Neumora Therapeutics Reports Encouraging Phase 1b Data For NMRA-511 In Alzheimer's Disease Agitation
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) on Monday announced positive results from a Phase 1b study of NMRA-511 in patients with agitation associated with Alzheimer's disease (AD).
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
#biopharmaceuticals #cancerresearch #clinicaltrials
www.nasdaq.com
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM. L,0013. HK), a commercial-stage, biopharmaceutical company, announced on Monday that it has commenced the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib combined with camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma or PDAC in China.
#Pharmaceuticals #ClinicalTrials #DrugDevelopment
www.nasdaq.com
Crinetics To Provide Update On PALSONIFY And Topline Results From Phase 2 Trial Of Atumelnant In CAH
(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) is scheduled to host a conference call to provide an update on its lead drug PALSONIFY's commercialisation and disclose topline results from the fourth cohort of its Phase 2 trial of Atumelnant in congenital adrenal hyperplasia or CAH, today.
#Tuberculosis #ClinicalTrial #Rifampin
www.medscape.com
High-Dose Rifampin Fails to Improve TB Meningitis Survival
High-dose rifampin -- 35 mg/kg daily -- administered for 8 weeks showed no reduction in mortality rate compared with standard-dose rifampin -- 10 mg/kg daily -- in patients with tuberculous meningitis but was accompanied by more early deaths and slower normalization of mental status.
#PancreaticCancer #CancerResearch #ClinicalTrials
markets.businessinsider.com
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N. J. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China.
S
#Pharmaceuticals #EndocrineDiseases #ClinicalTrials
www.streetinsider.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.
#Pharmaceuticals #ClinicalTrials #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.
#BrainComputerInterface #Neurosurgery #ClinicalTrials
www.mlive.com
University of Michigan opens brain-computer interface clinic in Ann Arbor
ANN ARBOR, MI -- One of the first brain-computer interface clinics in the country has opened in Ann Arbor.
University of Michigan Health opened its clinic to patients with severe motor and speech impairments on Tuesday, Dec.
C
#CancerResearch #PancreaticCancer #ClinicalTrials
www.courant.com
Pancreatic cancer is among the deadliest cancers. A new drug being tested at Penn is giving patients and doctors hope
PHILADELPHIA -- Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to stage 4 less than a year after her initial diagnosis.
#Gonorrhea #AntibioticResistance #ClinicalTrials
www.sciencedaily.com
New antibiotic pill shows promise against drug-resistant gonorrhea
Researchers are testing a new oral medication called zoliflodacin that could offer a simpler way to treat gonorrhea, especially strains that no longer respond well to existing antibiotics.
